Objective: To explore the expression of hsa_circ_0046701 in patients with glioma and its correlation with clinicopathological features and prognosis of glioma, and to study its clinical value. Methods: qRT-PCR was used to detect the expression of hsa_circ_0046701 in glioma tissues and normal brain tissues, and chi-square test was used to analyze the effects of different levels of hsa_circ_0046701 expression on the clinicopathological features of patients. The survival curve was drawn by Kaplan-Meier method, and the univariate and multivariate analysis of prognosis was performed by Cox proportional hazard regression model. Results: The expression level of hsa_circ_0046701 in gliomas was significantly higher than that in normal brain tissues, and the expression in grade Ⅲ-Ⅳ gliomas was higher than that grade Ⅰ-Ⅱ gliomas in WHO grade. The expression of hsa_circ_0046701 was significantly correlated with WHO grade, KPS score and postoperative recurrence, but not with age, sex, tumor size, number and location. The five-year survival rate of the group with high expression of hsa_circ_0046701 was lower than that of the group with low expression of hsa_circ_0046701. The patients with high expression of hsa_circ_0046701, had high WHO grade and the KPS score was less than 80. Postoperative recurrence was an independent prognostic factor for glioma patients. Conclusion: Hsa_circ_0046701 is highly expressed in gliomas, which is positively correlated with the malignant degree of gliomas, and can be used as a potential biological marker. High expression of hsa_circ_0046701, high WHO grade, KPS score < 80, postoperative recurrence are the key factors affecting the prognosis of patients, which can be used as independent prognostic factors for patients.